Navigation Links
Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
Date:8/7/2013

RICHMOND, Calif., Aug. 7, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:10 am ET on Wednesday, August 14, 2013, at the 2013 Wedbush Life Sciences Management Access Conference which will be held in New York City.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
2. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
3. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Reports First Quarter 2012 Financial Results
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
8. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... Va. (PRWEB) , ... October 02, 2019 , ... eKare’s ... prestigious NHS Digital Health Accelerator run by the East Midlands Academic Health Science Network ... the adoption of technology in NHS by providing support to develop and deploy solutions ...
(Date:9/24/2019)... ... September 24, 2019 , ... Drug resistance has been declared ... Health Organization, with MRSA becoming one of the most serious concerns. Hong Kong cannot ... cases of community-associated MRSA (CA-MRSA), or a seven-fold of the figure in 2007 – ...
(Date:9/22/2019)... ... September 20, 2019 , ... ZRT Laboratory ... testing in serum . BDNF plays a vital role in protecting existing neurons ... of new neurons in the brain involved in learning, memory, and higher thinking. ...
(Date:9/17/2019)... ... September 16, 2019 , ... When a lot of ... that allow for the complete 3D characterization of tissues through the use of confocal ... an imaging, image analysis and advanced cell culture focused contract research organization and today ...
Breaking Biology Technology:
(Date:10/10/2019)... ... October 09, 2019 , ... Calcium & Bone Health ... Hotel in Vancouver, Canada on September 23-24 for two days. The purpose of ... develop healthy bone and to prevent calcium-related diseases. The theme of this year ...
(Date:10/8/2019)... , ... October 07, 2019 , ... The future of ... the genetic level, resulting in people living longer, healthier lives. But it will be ... earth. , Leroy E. Hood, MD, PhD, Chief Strategy Officer and Co-Founder of the ...
(Date:10/3/2019)... HILL, Conn. (PRWEB) , ... October 02, 2019 ... ... and the leading source of financing and ongoing support for Connecticut’s innovative, growing ... an Israel-based fraud protection company for mobile payments and winner of the 2018 ...
Breaking Biology News(10 mins):